Long Term Vitamin D Therapy in HCV Treated Patients

• Status: Terminated
• Trial end date: 2013-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Treatment of hepatitis C virus (HCV) infection was carried out using pegylated interferon (PEG-IFN), ribavirin (RBV) and vitamin D (vit D) for 48 weeks in HCV genotypes 4a subjects. The purpose of this study is to determine the effect of vitamin D on liver affection in such patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dr. Nadia AbdelAaty AbdelKader
• Treatments: Ergocalciferols; Interferons; Ribavirin; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• Chronic HCV infection (positive HCV Ab more than 6 months)

• Treated with pegylated interferon and ribavirin

Exclusion Criteria:

• Coinfection with Hepatitis B or Hepatitis D or Human Immunodeficiency Virus

• Previous non response to antiviral therapy.

• Other causes of chronic liver diseases as schistosomiasis, Wilson disease and alcoholic liver disease.